All the above results would support the anti–inflammatory effect obtained in AL0035-treated groups by means of the reduction in pro–inflammatory bacteria and the maintenance of intestinal barrier integrity and functions by the modulation of tight junction proteins (ZO-1) in the colonic tissue and the regulation of anti/pro-inflammatory mediators, displaying the same ability of mesalazine in relieving TNBS-induced colitis symptoms. Here, TJP1 is linked to colitis.